Role of protease-activated receptor 2 in regulation of renin synthesis and secretion in mice
- 113 Downloads
It has been reported that the serine protease kallikrein stimulates and that aprotinin, a protease inhibitor, inhibits renal renin secretion. Since direct stimulation of the protease-activated receptor (PAR) 2 increases renin secretion in isolated perfused mouse kidneys, we hypothesized that activation of PAR2 receptors by serine proteases could be involved in the synthesis and secretion of renin in vivo. We therefore determined the response of plasma renin concentration (PRC) to acute intraperitoneal administration of the PAR2 agonist SLIGRL, isoproterenol, hydralazine, furosemide, losartan, or lipopolysaccharide in conscious wild-type (WT) and Par2-deficient mice. Basal PRC was not different in Par2-deficient mice compared with WT mice. All six acute treatments caused significant increases of PRC in both WT and Par2-deficient mice. The response was significantly lower only in endotoxin-treated Par2-deficient mice. Chronic treatment with losartan, low salt intake, the combination of both, or furosemide caused an increase of PRC and renin mRNA in WT mice, whereas a high salt intake caused a decrease. Alterations in PRC and renal renin mRNA expression were not different between WT and Par2 -/- mice in response to chronic treatments. Par2-deficiency did not alter furosemide-induced diuresis and natriuresis. Systolic blood pressure responses to chronic treatments were not different between WT and Par2 -/- mice. In conclusion, deficiency of Par2 receptors does not alter renin secretion and renin gene expression modulated by a variety of typical maneuvers. However, activation of Par2 receptors by serine proteases seems to be of importance for renin secretion in the context of inflammation.
KeywordsRenin Kidney F2RL1 Lipopolysaccharide Angiotensin
The technical assistance provided by Ramona Mogge and Andrea Agli is gratefully acknowledged.
Author contribution statement
LRT and KH conceived and designed the research. LRT conducted the experiments. LRT and KH analyzed the data. KH wrote the manuscript. All authors read and approved the manuscript.
Compliance with ethical standards
All procedures were performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and were approved by the local animal protection committee.
Conflict of interest
The authors declare that they have no conflict of interest.
- Abdallah RT, Keum JS, El-Shewy HM, Lee MH, Wang B, Gooz M, Luttrell DK, Luttrell LM, Jaffa AA (2010) Plasma kallikrein promotes epidermal growth factor receptor transactivation and signaling in vascular smooth muscle through direct activation of protease-activated receptors. J Biol Chem 285:35206–35215. https://doi.org/10.1074/jbc.M110.171769 CrossRefPubMedPubMedCentralGoogle Scholar
- Chung H, Ramachandran R, Hollenberg MD, Muruve DA (2013) Proteinase-activated receptor-2 transactivation of epidermal growth factor receptor and transforming growth factor-beta receptor signaling pathways contributes to renal fibrosis. J Biol Chem 288:37319–37331. https://doi.org/10.1074/jbc.M113.492793 CrossRefPubMedPubMedCentralGoogle Scholar
- D’Andrea MR, Derian CK, Leturcq D, Baker SM, Brunmark A, Ling P, Darrow AL, Santulli RJ, Brass LF, Andrade-Gordon P (1998) Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. J Histochem Cytochem 46:157–164. https://doi.org/10.1177/002215549804600204 CrossRefPubMedGoogle Scholar
- Damiano BP, Cheung WM, Santulli RJ, Fung-Leung WP, Ngo K, Ye RD, Darrow AL, Derian CK, de Garavilla L, Andrade-Gordon P (1999) Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. J Pharmacol Exp Ther 288:671–678PubMedGoogle Scholar
- Dudoignon E, Depret F, Legrand M (2019) Is the renin-angiotensin-aldosterone system good for the kidney in acute settings? Nephron:1–5. https://doi.org/10.1159/000499940
- Hocherl K, Gerl M, Schweda F (2011) Proteinase-activated receptors 1 and 2 exert opposite effects on renal renin release. Hypertension 58:611–618. https://doi.org/10.1161/HYPERTENSIONAHA.111.173229 CrossRefPubMedGoogle Scholar
- Jesmin S, Gando S, Zaedi S, Prodhan SH, Sawamura A, Miyauchi T, Hiroe M, Yamaguchi N (2009) Protease-activated receptor 2 blocking peptide counteracts endotoxin-induced inflammation and coagulation and ameliorates renal fibrin deposition in a rat model of acute renal failure. Shock 32:626–632. https://doi.org/10.1097/SHK.0b013e3181a5359c CrossRefPubMedGoogle Scholar
- Kim SM, Chen L, Faulhaber-Walter R, Oppermann M, Huang Y, Mizel D, Briggs JP, Schnermann J (2007a) Regulation of renin secretion and expression in mice deficient in beta1- and beta2-adrenergic receptors. Hypertension 50:103–109. https://doi.org/10.1161/HYPERTENSIONAHA.107.087577 CrossRefPubMedGoogle Scholar
- Mederle K, Meurer M, Castrop H, Hocherl K (2015) Inhibition of COX-1 attenuates the formation of thromboxane A2 and ameliorates the acute decrease in glomerular filtration rate in endotoxemic mice. Am J Physiol Renal Physiol 309:F332–F340. https://doi.org/10.1152/ajprenal.00567.2014 CrossRefPubMedGoogle Scholar
- Morla L, Brideau G, Fila M, Crambert G, Cheval L, Houillier P, Ramakrishnan S, Imbert-Teboul M, Doucet A (2013) Renal proteinase-activated receptor 2, a new actor in the control of blood pressure and plasma potassium level. J Biol Chem 288:10124–10131. https://doi.org/10.1074/jbc.M112.446393 CrossRefPubMedPubMedCentralGoogle Scholar
- Nasjletti A, Malik KU (1981) The renal kallikrein-kinin and prostaglandin systems interaction. Annu Rev Physiol 43:597–609. https://doi.org/10.1146/annurev.ph.43.030181.003121 CrossRefPubMedGoogle Scholar
- Neubauer B, Schrankl J, Steppan D, Neubauer K, Sequeira-Lopez ML, Pan L, Gomez RA, Coffman TM, Gross KW, Kurtz A, Wagner C (2018) Angiotensin II short-loop feedback: is there a role of Ang II for the regulation of the renin system in vivo? Hypertension 71:1075–1082. https://doi.org/10.1161/HYPERTENSIONAHA.117.10357 CrossRefPubMedPubMedCentralGoogle Scholar